Back to results
US 2019/0167605 A1Published application
Treatment of fragile x syndrome with cannabidiol
AssigneeZynerba Pharmaceuticals, Inc.
InventorsMarcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
Life of this patent
Estimating the term…
Abstract
The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
Claims7
1-30. (canceled)
A method of treating a human suffering from Fragile X Syndrome comprising:
- transdermally administering 250 mg or 500 mg of cannabidiol total daily to the human suffering from Fragile X Syndrome to effectively treat the Fragile X Syndrome in the human in need thereof.
Dependencies are inferred from the claim text.